21 research outputs found
withdrawn 2017 hrs ehra ecas aphrs solaece expert consensus statement on catheter and surgical ablation of atrial fibrillation
Get PDFn/
Synthesis, structural characterization and thromboxane A receptor antagonistic activity of 3-substituted 2-[(arylsulfonyl)imino]-2,3- dihydrothiazolyl derivatives
No full textThromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500)
No full textSCOPUS: ar.jFLWINinfo:eu-repo/semantics/publishe
Synthèse et évaluation biologique d’antagonistes non-carboxyliques du récepteur au thromboxane A2
Full text linkSynthèse et évaluation biologique de sulfonylurées en tant qu’antagonistes du thromboxane A2
Full text linkDesign, synthesis and biological evaluation of sulfonylureas as original non-prostanoïd thromboxane A2 receptor antagonists
Full text linkPharmacomodulation of torasemide led to original diuretic, neuroproptective anticonvulsant and antithrombotic drugs
No full textDesign, synthesis and biological evaluation of sulfonylureas as original non-prostanoid thromboxane A2 receptor antagonists
Full text linkDesign, synthesis and biological evaluation of sulfonylureas as original non-prostanoid thromboxane receptor antagonists
Full text linkPharmacomodulation of torasemide led to original diuretic, neuroprotective, anticonvulsant and antithrombotic drugs
Full text linkPharmacomodulation of torasemide, a diuretic sulfonylurea, led to the discovery of two novel diuretics, a sulfonylthiourea (BM 20) and a sulfonylcyanoguanidine (BM 106). BM 27, a lipophilic sulfonylurea, exhibited neuroprotective properties associated to an anticonvulsant activity. As BM 27, two lipophilic sulfonylthioureas (BM 11 and BM 34) revealed an anticonvulsant profile similar to that of phenytoin. Finally the synthesis of torasemide derivatives led to the development of a sulfonylcyanoguanidine (BM 144) with a thromboxane A2 antagonist potency.SCOPUS: sh.jinfo:eu-repo/semantics/publishe
